WordNet

(law) an interest in an estate that reverts to the grantor (or his heirs) at the end of some period (e.g., the death of the grantee)
turning in the opposite direction (同)reverse, reversal, turnabout, turnaround
(genetics) a return to a normal phenotype (usually resulting from a second mutation)
go back to a previous state; "We reverted to the old rules" (同)return, retrovert, regress, turn_back
undergo reversion, as in a mutation
of or relating to or involving a reversion (especially a legal reversion); "reversionary annuity"; "reversionary interest"
an annuity payable to one person in the event that someone else is unable to receive it (同)survivorship annuity
(law) a party who is entitled to an estate in reversion

PrepTutorEJDIC

〈U〉(元の状態・習慣・話題などに)逆戻りすること,復帰・〈U〉〈C〉(生物の)先祖返り,融世遺伝 / 〈U〉不動産(財産)の複帰(権);財産相続権
(元の状態・話題・習慣などへ)戻る,逆戻りする《+to》+『名』(doing)》 / 〈生物が〉先祖返りする / 〈財産・権利などが〉(前の所有者などに)復帰する《+『to』+『名』》
復帰権のある・復帰権のある，将来享有すべき.

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/02/28 16:56:30」(JST)

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

EGF Suppresses the Initiation and Drives the Reversion of TGF-β1-induced Transition in Hepatic Oval Cells Showing the Plasticity of Progenitor Cells.

Wang P1,2,3, Yang AT1,2, Cong M1,2, Liu TH1,2, Zhang D2, Huang J2, Tong XF1,2, Zhu ST2, Xu Y1,2, Tang SZ1,2, Wang BE1,2, Ma H1,2, Jia JD1,2, You H1,2.
Journal of cellular physiology.J Cell Physiol.2015 Oct;230(10):2362-70. doi: 10.1002/jcp.24962.
Transforming growth factor-β1 (TGF-β1) induces hepatic progenitors to tumor initiating cells through epithelial-mesenchymal transition (EMT), thus raising an important drawback for stem cell-based therapy. How to block and reverse TGF-β1-induced transition is crucial for progenitors' clinical app
PMID 25739869

Cetuximab directly inhibits P-glycoprotein function in vitro independently of EGFR binding.

Chu C1, Noël-Hudson MS2, Bénard J3, Ha-Duong T4, Allaoui F2, Farinotti R2, Bonhomme-Faivre L5.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.Eur J Pharm Sci.2015 Aug 30;76:18-26. doi: 10.1016/j.ejps.2015.04.014. Epub 2015 Apr 27.
PURPOSE: Cancer chemotherapy typically combines anticancer drugs from different mechanisms of action. However, cancer cells could become resistant to chemotherapy via P-gp or other ATP binding cassette proteins. The objective of this study was to evaluate whether cetuximab, monoclonal antibody direc
PMID 25930120

Negative Epistasis and Evolvability in TEM-1 β-Lactamase-The Thin Line between an Enzyme's Conformational Freedom and Disorder.

Dellus-Gur E1, Elias M2, Caselli E3, Prati F3, Salverda ML4, de Visser JA5, Fraser JS6, Tawfik DS7.
Journal of molecular biology.J Mol Biol.2015 Jul 17;427(14):2396-409. doi: 10.1016/j.jmb.2015.05.011. Epub 2015 May 22.
Epistasis is a key factor in evolution since it determines which combinations of mutations provide adaptive solutions and which mutational pathways toward these solutions are accessible by natural selection. There is growing evidence for the pervasiveness of sign epistasis-a complete reversion of mu
PMID 26004540

Multifunctional mesoporous silica nanoparticles mediated co-delivery of paclitaxel and tetrandrine for overcoming multidrug resistance.

Jia L1, Li Z2, Shen J3, Zheng D4, Tian X3, Guo H3, Chang P1.
International journal of pharmaceutics.Int J Pharm.2015 Jul 15;489(1-2):318-30. doi: 10.1016/j.ijpharm.2015.05.010. Epub 2015 May 5.
The objective of the study is to fabricate multifunctional mesoporous silica nanoparticles for achieving co-delivery of conventional antitumor drug paclitaxel (PTX) and the multidrug resistance reversal agent tetrandrine (TET) expecting to overcome multidrug resistance of MCF-7/ADR cells. The nanopa
PMID 25956050

河合竜也,津田博史,カワイタツヤ,ツダヒロシ,Kawai Tatsuya,Tsuda Hiroshi
同志社大学理工学研究報告 55(4), 341-348, 2015-01
… In the previous paper, we analyzed the mean reversion of KINK and verified that it reverts to within a certain range over time. …
NAID 120005550051